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Objectives. This study was designed to examine whether over- 
sized implantation of the new, less shortening Wallstent provides 
a more favorable long-term clinical and angiographic outcome in 
chronic total occlusions than does conventional coronary balloon 
angioplasty. 
Background. Restenosis and reocclusion remain major limita- 
tions of balloon angioplasty for chronic total occlusions. Enforced 
mechanical remodeling by implantation of the oversized Wallstent 
may prevent elastic recoil and improve accommodation of intimal 
hyperplasia. 
Methods. Lumen dimension was measured by a computer- 
based quantitative coronary angiography system (CAAS II). These 
measurements (before and after intervention and at 6-month 
follow-up) were compared between the groups with Wallstent 
implantation (20 lesions, 20 patients) and conventional balloon 
angioplasty (266 lesions, 249 patients) for treatment of chronic 
total occlusion. Acute gain (minimal lumen diameter after inter- 
vention minus that before intervention), late loss (minimal lumen 
diameter after intervention minus that at follow-up) and net gain 
(acute gain minus late loss) were examined. 
Results. Wallstent deployment was successful in all patients. 
High pressure intra-Wallstent balloon inflation (mean + SD 14 _+ 
3 atm) was performed in all lesions. Although vessel size did not 
differ between the Wallstent and balloon angioplasty groups, acute 
gain was significantly greater in the Wallstent group (2.96 +- 0.55 
vs. 1.61 -+ 0.34 mm, p < 0.0001). Although late loss was also 
significantly larger in the Wallstent group (0.81 -+ 0.95 vs. 0.43 -+ 
0.68 ram, p < 0.05), net gain was still significantly greater in this 
group (2.27 "4- 1.00 vs. 1.18 --. 0.69 ram, p < 0.0001). Angiographic 
restenosis (> 50% diameter stenosis) occurred at 6 months in 29% 
of lesions in the Wallstent group and in 45% of those in the 
balloon angioplasty group (p = 0.5150). 
Conclusions. Implantation of the oversized WaUstent, with full 
coverage of the lesion length, ensures resetting of the vessel size to 
its original caliber before disease and allows greater accommoda- 
tion of intimal hyperplasia and chronic vessel recoil. Walistent 
implantation provides a more favorable short- and long-term 
clinical and angiographic outcome than does conventional balloon 
angioplasty for chronic total occlusions. 
(J Am CoU Cardiol 1996;28:354- 60) 
The rate of restenosis i  significantly higher after successful 
dilation of total coronary occlusions than after successful 
dilation of nonoccluded stenoses (1-3). We (3) recently dem- 
onstrated, using both a categoric and a continuous approach, 
that this higher restenosis rate is mainly due to an increased 
rate of occlusion at follow-up angiography. Multivariate anal- 
ysis suggested that this increased rate is specifically related to 
total inflation time and vessel reference diameter after inter- 
vention. For several reasons the acute lumen diameter ob- 
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tained after successful balloon angioplasty is significantly 
smaller for chronic total occlusions than for nonoccluded 
stenoses (3). The new less shortening self-expanding Wallstent 
is characterized by longitudinal flexibility, a protective mem- 
brane, a low profile and a customized range of diameters and 
lengths (4-6). The recent modification in braiding angle and 
stent strut have resulted in a new device with less shortening on 
expansion and a concomitant reduction in radial force and 
improvement in radiopacity (4-6). These modifications may 
convey a lower restenosis rate because of lower metallic 
surface per segment and increased feasibility of stent delivery 
because of higher visibility and less shortening when the steut 
expands. 
We hypothesized that enforced mechanical remodeling by 
oversized stent implantation after coronal?/ angioplasty may 
lead to improved local flow dynamics, with a resulting low 
incidence of acute and subacute occlusion as well as prevention 
of chronic elastic recoil and improved accommodation of
reactive intimal hyperplasia. The new, less shortening Wall- 
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stent is ideal for this situation because it is self-expanding, 
comes in a customized range of long lengths (up to 42 ram) and 
large diameters (up to 6.0 ram). We examined this strategy of 
oversized Wallstent deployment in 20 patients after successful 
laser or balloon angioplasty. Quantitative coronary angio- 
graphic analysis was performed before intervention, after 
balloon angioplasty, after high pressure balloon angioplasty 
after oversized Wallstent deployment ("Swiss kiss") and at 
6-month follow-up. The results were compared with those in 
patients with total occlusions undergoing successful balloon 
angioplasty and quantitative angiographic follow-up at 6 
months in the same angiographic core laboratory. 
Methods  
Study patients. Wallstent implantation group. To deter- 
mine the feasibility and efficacy of deployment ofthe new, less 
shortening Wallstent in patients with chronic total occlusion, 
we deployed 25 Wallstents in 20 native coronary artery lesions 
in 20 patients who had coronary balloon or laser angioplasty of 
chronic total occlusion >3 months old. 
Balloon angioplas~ group. To provide further insight into 
the potential short- and long-term mechanisms involved in 
implantations of the grossly oversized Wallstent, we compared 
our serial angiographic measurements with those of 266 arter- 
ies with total occlusion in 249 patients undergoing successful 
balloon angioplasty. This study group was selected from 3,582 
patients with significant native coronary artery stenosis who 
were prospectively enrolled in four major restenosis tudies 
and underwent successful coronary angioplasty (7-10). Quan- 
titative angiographic assessment before and after balloon 
angioplasty and at 6-month follow up was performed with use 
of the same methodology and at the same angiographic core 
laboratory (3) for all 266 lesions in 249 patients. 
Laser and balloon angioplasty. Coronary angioplasty was 
performed according to standard clinical practice by the fem- 
oral approach at the Thoraxcenter (Rotterdam, The Nether- 
lands). Laser angioplasty was applied in patients who had had 
previously unsuccessful balloon angioplasty. Primary laser an- 
gioplasty using a laser wire and catheter was carried out in six 
patients. Laser wire (0.018-in. [0.046-cm] diameter, Spectra- 
netics) was used to pass into and beyond alesion with chronic 
total occlusion when a flexible guide wire (0.014 in. [0.036 cm]) 
failed to cross the lesion (11,12). Excimer laser system (Spec- 
tranetics CVX 300) produced laser fluency with an energy level 
of 60 mJ/mm 2and a pulse repetition frequency of 25 Hz. The 
laser wire was advanced -1 mm/s. After the wire successfully 
crossed the lesion, a laser catheter (1.4- or 1.7-mm diameter, 
Spectranetics) was passed over the wire to enlarge the coro- 
nary lumen (11,12). After the successful laser procedure, 
adjunctive balloon angioplasty was carried out. In the remain- 
ing 14 patients balloon angioplasty was performed after suc- 
cessful crossing with 0.014-in. guide wire. During the primary 
balloon angioplasty the balloon diameter was 2.67 _+ 0.66 mm 
and the maximal inflation pressure was 10.3 2 3.0 atm. 
Figure 1. Left panel, Angiogram showing total occlusion of a mid-right 
coronary artery and a maximal vessel diameter of 2.90 mm in the 
proximal segment. A Wallstent (diameter 4.5 ram, length 35 mm) 
1.60 mm larger than the maximal vessel diameter was deployed (right 
panel). Minimal lumen diameter increased from 0 to 2.61 mm, and 
Thrombolysis in Myocardial Infarction (TIMI) grade 3 flow was 
restored. 
Wallstent implantation. Intracoronary ultrasound studies 
(13-16) have reported that atherosclerotic plaque is commonly 
observed in angiographically normal proximal reference seg- 
ments in patients with significant coronary stenosis. We there- 
fore used the maximal vessel diameter, which may be closer to 
the original vessel diameter in the nondiseased condition than 
is the interpolated reference diameter traditionally used for 
stent sizing. After determination f the maximal vessel diam- 
eter on the diameter function of the on-line quantitative 
Coronary Angiographic Analysis System (CAlkS II), a Wall- 
stent with a nominal diameter 1.5 mm greater than the 
maximal vessel diameter and nominal length 5 to 10 mm longer 
than the lesion length was selected (Fig. 1). Of the 25 stents 
used in 20 lesions, 1 had a diameter of 4 mm, 2 of 4.5 ram, 6 of 
5 ram, 9 of 5.5 mm and 7 of 6 mm. Eleven of the 25 stents had 
a length of 23 to 28 ram, 8 of 35 mm and 6 of 42 mm. Fifteen 
patients received one Wallstent and the remaining five patients 
received two Wallstents. After delivery of the stent, high 
pressure inflations ("Swiss kiss", 14.0 _+ 3.3 arm) using balloon 
diameters of 3.9 _+ 0.7 mm to optimize stent expansion were 
performed in all 20 patients. 
Anticoagulant therapy. Patients were given an intravenous 
bolus dose of 10,000 IU of heparin, and subsequently 5,000 
IU at the beginning of the intervention, as required to 
maintain the activated clotting time >300 s throughout the 
procedure. In this early experience a standardized postint- 
ervention anticoagulant regimen was used (17,18): One hour 
after removal of the femoral sheath, a heparin intravenous 
infusion was begun to maintain activated partial thrombo- 
plastin time between 70 and 90 s until oral anticoagulant 
therapy (warfarin sodium [Coumadin]) had achieved a 
prothrombin time international normalized ratio of 2.5 to 
3.5. Coumadin was prescribed for 3 months after stent 
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implantation and aspirin indefinitely (17,18). Ticlopidine 
was not used. 
Study end points and definitions. Procedural success was 
defined as technically successful deployment ofthe stent in the 
absence of any adverse cardiac events, defined as acute or 
subacute stent hrombosis, repeat intervention, coronary artery 
bypass urgery, myocardial infarction or death. Angiographic 
success was defined as a <30% residual diameter stenosis 
after final deployment of the stent. The primary clinical end 
point of the study was the occurrence of any adverse cardiac 
event. Subacute thrombosis was defined as a clinical event 
leading to cardiac catheterization that identified stent 
thrombosis within 14 days of stent deployment. Angio- 
graphic restenosis was defined as lumen narrowing ->50% 
diameter stenosis at follow-up. Long-term clinical outcome 
included all cardiovascular events occurring within 6 months 
of stent deployment. 
Quantitative coronary angiographic analysis. The new 
version of the computer-based CAAS II system (19) was used 
to perform on-line quantitative analysis (for immediate guid- 
ance of stent sizing in the catheterization laboratory) and the 
subsequent off-line cine film analysis. In the CAAS analysis, 
which has previously been described elsewhere (20-25), the 
entire 18- x 24-mm cine frame is digitized at a resolution of 
1,329 × 1,772 pixels. Correction for pincushion distortion is 
performed before analysis. Boundaries of a selected coronary 
segment are detected automatically. The absolute diameter of 
the stenosis (in mm) is determined by using the guiding 
catheter as a scaling device (26). To standardize the method of 
analysis of the initial and follow-up angiograms, the following 
measures were taken: All study frames elected for analysis 
were end-diastolic to minimize motion artifact; arterial 
segments were measured between the same identifiable 
branch points after administration of isosorbide dinitrate 
(27-30). 
Quantitative angiographic variables. Acute gain and late 
loss represent the improvement in minimal umen diameter 
achieved at intervention (minimal lumen diameter after stent- 
ing minus that before stenting) and the changes at follow-up 
(minimal umen diameter after stenting minus that at follow- 
up), respectively. Net gain (gain minus loss) was examined. 
Vessel size was defined as a interpolated reference diameter 
after balloon angioplasty (31). Because the algorithm cannot 
measure total occlusions, a value of 0 mm was imputed for the 
minimal umen diameter, and the reference diameter after 
balloon angioplasty was substituted for that before interven- 
tion. Net gain index (net gain divided by the reference diam- 
eter before angioplasty), relative loss (loss divided by the 
reference diameter before intervention) and loss index (loss 
divided by gain) were studied. 
Statistical analysis. Data were analyzed by using the SAS 
statistical software package. Categoric variables are presented 
as absolute numbers (%). Continuous variables are expressed 
as mean value _+ 1 SD. Differences between groups were 
evaluated by using adjusted chi-square tests for categoric 
Table 1. Clinical and Angiographic Characteristics of the Patients 
Wallstent Balloon 
Implantation Angioplasty 
Group Group p 
(n = 20 patients) (n = 249 patients) Value 
Male 95.0% 85.1% 0.3765 
Age (yr) 55.9 -+ 9.3 54.4 +_ 9.6 0.5011 
Prior myocardial infarction 50.0% 54.2% 0.8958 
Prior successful balloon 5.0% 3.6% 0.5445 
angioplasty 
Prior coronary bypass urgery 10.0% 1.6% 0.0971 
Coronary, risk factors 
Hypercholesterolemia 30.0% 33.3% 0.9538 
Systemic hypertension 30.0% 30.1% 0.8087 
Cigarettes (ever smoked) 65.0% 73.l% 0.6034 
Diabetes 10.0% 10.8% 0.7966 
CCS angina class 
None 5.0% 6.0% 0.7603 
l 10.0% 10.0% 0.7032 
II 35.0% 33.7% 0.8961 
Ill 30.0% 28.9% 0.4736 
IV 20.0% 21.3% 0.8815 
No. of diseased vessels 
l 60.0% 61.0% 0.8838 
2 30.0% 34.5% 0.8676 
3 10.0% 3.6% 0.4233 
Lesion location 
RCA 70.0% 33.7% 0.0026 
LAD 30.0% 39.4% 0.5564 
LCx 0 26.9% 0.0160 
TIMI flow before intervention 
TIMI 0 75.0% 41.0% 0.0063 
TIM1 1 25.0% 59.0% 0.0063 
Data presented are percent of patients or mean value _+ SD. CCS = 
Canadian Cardiovascular Society; TIMI = Thrombolysis n Myocardial Infarc- 
tion grade flow (32). 
variables and Student tests for continuous variables. A p 
value < 0.05 was considered significant. 
Resu l ts  
Baseline clinical and angiographic characteristics in the 
Wallstent and balloon angioplasty groups (Table 1). No dif- 
ference was found between the Wallstent implantation and 
balloon angioplasty groups in gender, age, previous myocardial 
infarction, previous successful balloon angioplasty, previous 
coronary bypass urgery, coronary risk factors, angina class 
or number of diseased vessels. The incidence of absolute 
total occlusions (Thrombolysis in Myocardial Infarction 
[TIMI] grade 0 [32]) was significantly higher in the Wall- 
stent group than in the balloon angioplasty group. The 
Wallstent was predominantly deployed in the right coronary 
artery, which has few significant side branches at risk of 
occlusion by full coverage of a long lesion using the Wall- 
stent (4). 
Clinical outcome. Delivery of all 25 Wallstents was possi- 
ble, and no cardiac event occurred during the procedure. 
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Figure 2. Changes inminimal lumen diameter (MLD) and reference 
diameter (RD) in 20 lesions from before (pre) intervention through 
the periods after balloon angioplasty (post BA) and after stent 
implantation (post stent) to follow-up. Minimal lumen diameter 
improved markedly after Wallstent implantation a d the performance 
of a Swiss Kiss. 
,oo I 
75 
cO 
CI 50 
25 
I00 % 
t 16o/o 
36 % 
pre post BA post stent follow-up 
Figure 4. Changes inpercent diameter stenosis (% DS) in 20 lesions 
from before intervention (pre) through after balloon angioplasty (post 
BA) and after stent implantation (post stent) to follow-up. There was 
a marked ecrease in residual stenosis after Wallstent implantation 
and the performance of a "Swiss kiss". 
Angiographic success (<30% diameter stenosis) was achieved 
in all patients with Wallstent implantation. One patient sus- 
tained a subacute occlusion on day 1 associated with a 
non-Q wave myocardial infarction (creatine kinase 228 
IU/liter) and was immediately treated by balloon angioplasty, 
which promptly restored TIMI grade 3 flow. Of the 19 patients 
in the Wallstent group eligible for 6-month angiographic 
follow-up, 2 asymptomatic patients declined restudy. Thus, the 
angiographic follow-up rate of the Wallstent group was 89%, a 
rate comparable to the 86% rate in the control balloon 
angioplasty group (3). Angiographic restenosis (->50% diam- 
eter stenosis) at 6 months occurred in 5 (29%) of 17 lesions in 
the Wallstent group and in 119 (45%) of 266 lesions in the 
balloon angioplasty group. The overall event-free survival rate 
at 6-month follow-up was 75% (15 of 20 patients) in the 
Wallstent group and 71% (195 of 249 patients) in the balloon 
angioplasty group. 
Quantitative angiographie analysis in the Wallstent group. 
The average nominal diameter of the Wallstents used was 
1.82 _+ 0.83 mm greater than the maximal vessel diameter and 
11.0 _+ 7.3 mm longer than the lesion length. Minimal lumen 
diameter increased from 0 mm before intervention to 1.10 + 
0.28 mm after balloon angioplasty (Fig. 2). After stent implan- 
tation, high pressure balloon dilation of 14.0 --2- 3.3 atm ("Swiss 
kiss") using balloons of 3.9 + 0.7-ram diameter was performed 
in all lesions. Implantation of the Wallstent further increased 
the minimal lumen diameter to 2.96 _+ 0.55 mm (Fig. 2). At 
6-month follow-up, minimal lumen diameter decreased to 
2.06 +_ 0.92 ram. Figure 3 provides an example of the serial 
angiographic outcome in an individual patient. Figure 4 shows 
percent diameter changes from the period before intervention 
through the period after stent implantation to6-month follow- 
up. 
Quantitative angiographic omparison with the group un- 
dergoing balloon angioplasty (Table 2). No difference was 
found in vessel size (interpolated reference diameter before 
intervention) between the Wallstent and balloon angioplasty 
groups. There was a significantly greater eference diameter 
after intervention i the Wallstent group, and this difference 
remained at follow-up. The minimal lumen diameter increased 
substantially more after Wallstent implantation, asreflected in 
the substantially ower percent residual stenosis. At follow-up, 
although the absolute loss was significantly higher in the 
Wallstent group, the greater initial gain allowed improved 
accommodation of the intimal hyperplasia, and both the 
minimal lumen diameter and percent diameter stenosis at 
follow-up were significantly lower in the Wallstent group. 
Although the restenosis rate using the categoric approach 
Figure 3. Coronary angiograms of the right cor- 
onary artery in a patient with total occlusion 
before balloon angioplasty (A). After balloon 
angioplasty a Wallstent (nominal diameter 
6.0 ram, length 42 ram) was deployed. The ra- 
diopaque stent delivery system and the markers 
can be seen during deployment (B). After Wall- 
stent deployment, minimal lumen diameter was 
3.06 mm in association with a 15% residual 
diameter stenosis (C). Follow-up angiography at 
6 months revealed a minimal lumen diameter of 
2.16 mm in association with a 35% diameter 
stenosis (D). 
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Table 2. Quantitative Angiographic Analysis Results in the 
Wallstent and Balloon Angioplasty Groups 
Wallstent Balloon 
Implantation Angioplasty 
Group Group 
(n - 20 lesions) (n - 266 lesions) p Value 
Reference diameter (mm) 
Before stent implantation 2.49 _+ 0.67 2.46 _+ 0.49 0.7976 
After intervention 3.51 _+ 0.55 2.46 +_ 0.49 < 0.0001 
At follow-up 3.24 ± 0.72 2.60 ± 0.55 < 0.0001 
Minimal lumen diameter (mm) 
Before intervention 0 0 - -  
After intervention 2.96 _+ 0.55 1.61 + 0.34 < 0.0001 
At follow-up 2.06 ± 0.92 1.18 _+ 0.69 < 0.0001 
Differences in minimal umen 
diameter (ram) 
Absolute gain 2.96 ± 0.55 1.61 _+ 0,34 < 0.0001 
Relative gain 1.19 _+ 0.30 0.66 _+ 0,09 < 0.0001 
Absolute loss 0.81 _+ 0.95 0.43 _+ 0,68 0.0201 
Relative loss 0.33 + 0.39 0.17 ± 0.28 0.0175 
Absolute net gain 2.27 _+ 1.00 1.18 _+ 0.69 < 0.0001 
Net gain index 0.92 + 0.40 0.48 + 0.28 < 0.0001 
Loss index 0.27 ± 0.31 0.26 ± 0.43 0.9189 
Percent diameter stenosis (% DS) 
Before intervention 100 100 - -  
After intervention 15.85 _+ 6.33 34.16 _+ 8.46 < 0.0001 
At follow-up 36.38 _+ 24.78 54.08 +_ 25.67 0.0031 
% DS at follow-up >-50% 29.41% 44.74% 0.5150 
Data presented are mean value + 8D or percent of lesions. 
tended to be lower in the Wallstent group, this difference did 
not achieve statistical significance. 
Discuss ion  
Our study showed that implantation fthe grossly oversized 
Wallstent can be safely and successfully performed in patients 
with total coronary occlusion. Furthermore, after successful 
delivery of the stent, angiographic success, as defined by <30% 
residual diameter stenosis, can be achieved in all cases. Despite 
the propensity o reocclusion of lesions in this group, Wallstent 
deployment resulted in a low risk of acute or subacute stent 
thrombosis and a low rate of restenosis and reocclusion at 
6-month follow-up. Thus, our policy of oversized Wallstent 
implantation resulted in a resetting of vessel size and a 
tendency toward a lower restenosis rate than that of occlusions 
undergoing standard balloon angioplasty. 
Reasons for high delivery success rate and safety. The high 
delivery success rate may be explained by the low profile 
(1.57 mm) and longitudinal flexibility of the Wallstent, which 
allow successful negotiation of tortuous vessels. Furthermore, 
the protective rolling membrane of the Wallstent prevents 
migration of the stent during negotiation of the target lesion, 
and the fine mesh structure of the device may prevent distal 
embolization of friable tissue from the recanalized total occlu- 
sion after successful laser or balloon angioplasty. Although a 
previous tudy (33) of angioplasty with deliberately oversized 
balloons in coronary stenoses uggested that that procedure 
may result in a higher rate of acute complications, the self- 
expanding nature of the Wallstent and its fine mesh structure 
are probably also responsible (by providing support and scaf- 
folding for the vessel wall) for the safe deployment of such 
grossly oversized stents in total occlusions. 
Comparison with balloon angioplasty group. By compar- 
ing our results with those of a group of total occlusions 
undergoing coronary balloon angioplasty and 6-month quanti- 
tative angiographic follow-up in the same angiographic core 
laboratory, we were able to demonstrate hat our policy of 
gross oversizing does indeed result in resetting of the vessel 
size to what is assumed to be its original state before disease. 
Furthermore, this oversizing results in a minimal lumen diam- 
eter after implantation that is significantly larger than the 
balloon angioplasty group reference diameter. Thus, despite 
the greater absolute and relative loss during follow-up of the 
Wallstent, the minimal lumen diameter at follow-up was 
significantly higher and the percent stenosis lower in this 
group. Although the resulting reduction in the categoric 
restenosis rate did not achieve statistical significance, this may 
have been due to the small number of lesions in our Wallstent 
group. The loss index was almost identical in both groups, 
-0.26 compared to a reported loss index of 0.50 for nonoc- 
eluded stenoses (34,35), suggesting that although the vessel 
reaction is similar after either balloon dilation or grossly 
oversized stent implantation, the relative fibroproliferative 
response in total occlusions is only half that seen in nonoc- 
eluded stenoses (34). This observation may represent signifi- 
cant differences in the underlying pathologic substrate, with 
total occlusions having less normal vessel wall and vessel media 
with which to mount a substantial fibroproliferative r sponse 
(36,37). Alternatively, differences in elastin content may result 
in less chronic recoil and vessel remodeling in successfully 
dilated occlusions (36,37). 
Comparison with other stents for the treatment of total 
occlusions. Previous tudies (38-41) have also examined stent 
implantation for the treatment of total coronary occlusions as 
elective therapy or as therapy for suboptimal results or for 
acute or threatened vessel closure. Depending on the indica- 
tion and type of stent used, follow-up angiographic restenosis 
rates have varied from 24% to 57%; the highest rate was 
obtained with the Gianturco-Roubin stent used in bailout 
situations. Our results compare favorably with these previously 
published data, and we believe that the Wallstent has some 
additional advantages over other stent designs in total coro- 
nary occlusions. These include the customized length of up to 
42 mm, which enables full coverage of the totally occluded 
lesion and avoids multiple stenting, which is more time- 
consuming and is also more likely to result in subacute 
thrombosis (42). The larger expanded iameter of up to 
6.0 mm also allows implantation of the grossly oversized 
Wallstent and resetting of the previously occluded vessel to its 
original condition before disease. Additionally, the high flexi- 
bility of the Wallstent allows more natural bending and 
tortuosity, factors that may be more favorable to dynamic 
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coronary flow. The self-expanding characteristics of the stent 
may play a role in preserving the large initial gain during 
follow-up by exerting a persisting strong radial force. 
Limitations of study. Our study has several imitations: 
1) Because our study numbers are small, the data need to be 
confirmed by larger multicenter studies. 2) We used an un- 
matched control group of lesions undergoing successful bal- 
loon angioplasty and quantitative angiographic follow-up for 
comparison. Differences in study patients and procedural 
characteristics between the Wallstent and balloon angioplasty 
groups may have exerted some influence on clinical and 
angiographic outcome. For example, there are significant 
differences between the left anterior descending and right 
coronary arteries in local flow dynamics, vessel geometry, 
external compressive forces (43) and propensity to restenosis 
(44). The predominance of right coronary artery lesions in our 
stent group may have had a substantial influence on the 
subsequent risk of occlusion and restenosis. Although there 
was a greater incidence of TIMI grade 0 lesions in the stent 
group, there is no evidence to suggest that these lesions are 
either more or less prone to restenosis than TIMI grade 1 
lesions (3). Similarly, although patients in the Wallstent group 
received anticoagulant therapy for 3 months after intervention, 
there is no evidence to suggest that his treatment may have led 
to a reduction in restenosis (45). 
Clinical implications. Recanalization of total occlusions 
remains limited by a higher estenosis rate than that seen after 
successful dilation of nonocclusive stenoses. Our study sug- 
gests not only that implantation of the grossly oversized new 
Wallstent is feasible and safe but that the resulting mechanical 
remodeling of the vessel can improve local flow dynamics with 
a resulting low incidence of subacute occlusion and prevention 
of late elastic recoil enabling increased accommodation f late 
lumen loss during follow-up. Our results need to be confirmed 
in larger, multicenter, randomized studies but suggest that a 
policy of implantation of the grossly oversized Wallstent in 
patients with total occlusion will result in a lower angiographic 
restenosis rate and improved clinical outcome. Adoption of a 
policy of gross oversizing with more rigid, balloon-expandable 
stents, such as the Palmaz-Schatz stent, may be entirely 
inappropriate and unsafe. Thus, the implications of our study 
should be limited to the new self-expanding, less shortening 
Wallstent. Finally, because the Wallstent is a fine mesh stent, 
performing angioplasty to a side branch through it is techni- 
cally very difficult. Furthermore, even if angioplasty were 
performed for disease in a side branch before stent deploy- 
ment in the main vessel, difficulties would be encountered if 
restenosis occurred. Additionally, a certain amount of intimal 
hyperplasia is anticipated inside the Wallstent; thus, if a side 
branch has a significant untreated narrowing at its origin 
before stent implantation in the main vessel, there is a 
significant risk of disease progression during follow-up. Be- 
cause of these considerations the Wallstent was used predom- 
inantly in the right coronary artery in this and previous tudies 
(4), and its use will be more limited in the left coronary system. 
Conclusions. The safety and feasibility of implantation of
the oversized Wallstent for the treatment of chronic total 
coronary occlusions were demonstrated. Oversized Wallstent 
implantation, with full coverage of the lesion length, ensures 
resetting of the vessel size to its original caliber before disease 
in patients with chronic total occlusion and allows greater 
accommodation f intimal hyperplasia nd chronic vessel 
recoil. In comparison with conventional balloon angioplasty, 
oversized Wallstent implantation conveys a more favorable 
short- and long-term clinical and angiographic outcome. 
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